Expression of NUCB2/nesfatin-1 in the taste buds of rats

Xun Cao1), Xiao Zhou2), Yang Cao1), Xiao-Min Liu1) and Li-Hong Zhou1)

1) Department of Endocrinology, Harbin Medical University, Harbin 150001, Heilongjiang Province, China
2) Department of Human Anatomy and Embryology, Harbin Medical University, Harbin 150001, Heilongjiang Province, China

Abstract. Nesfatin-1, an anorexigenic peptide derived from nucleobindin 2 (NUCB2), is closely involved in feeding behavior, glycometabolism, and satiety regulation. Some studies show that NUCB2/nesfatin-1 is highly expressed and interacts with many appetite-regulating peptides that are co-expressed in the gastrointestinal tract. However, it remains unclear whether nesfatin-1 is expressed and interacts similarly in taste buds. Glucagon-like peptide-1 (GLP-1), a well-known appetite down-regulating peptide, is associated with changes in the expression of nesfatin-1. Therefore, we measured the expression of the NUCB2 gene and the distribution of nesfatin-1-immunoreactive cells and investigated whether these variables change in taste buds of circumvallate papillae (CV) from rats with type 2 diabetes (T2DM) after treatment with liraglutide, a GLP-1 receptor agonist. The results showed that nesfatin-1 immunoreactive cells were localized in the taste buds of rat CV. Quantitative RT-PCR showed a significantly lower expression of NUCB2 mRNA in the taste buds of diabetic control rats (T2DM-C) than in those of the normal control group (NC) and a higher level of NUCB2 in the liraglutide treated group (T2DM + LIR) than either the T2DM-C or the NC groups. Changes in the expression of NUCB2 in the rat hypothalamus were opposite to those in CV taste buds. In summary, we found that rat CV taste buds express NUCB2/nesfatin-1, and that this expression decreases significantly in T2DM and increases after treatment with liraglutide in rat CV. This indicates that nesfatin-1 could be an important factor in the regulation of gustatory function, feeding and perhaps energy homeostasis.

Key words: Nesfatin-1, Taste, T2DM, Liraglutide

NESFATIN-1 is an 82-amino-acid peptide derived from posttranslational processing of the N-terminal fragment of nucleobindin 2 (NUCB2), which was identified originally as an anorexigenic hypothalamic neuropeptide [1]. This peptide exhibits many functions in different tissues, especially on feeding and glycometabolism. Nesfatin-1 can decrease food intake and body weight, delay gastric emptying, and increase glucose-induced insulin secretion and glucose elimination [2-4]. Nesfatin-1 can also pass through the blood-brain barrier without saturation, suggesting a peripheral source [5]. Either peripheral or central administration of nesfatin-1 can reduce food intake through a leptin-independent mechanism [6]. In addition to the hypothalamus, NUCB2/nesfatin-1 is broadly expressed in peripheral tissues including the gastrointestinal tract [7, 8]. However, there are no reports about whether NUCB2/nesfatin-1 is expressed in rat taste buds.

Recently, a number of reports have shown that many gastrointestinal acting peptides, such as cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and ghrelin that are classically considered to regulate appetite, also exist in taste cells and may play a role in the gustatory system [9-12]. Of these peptides, ghrelin is the only known hormone originating from gastric X/A-like cells that can stimulate food intake centrally [13]. Interestingly, ghrelin and nesfatin-1 are co-localized in gastric X/A-like cells, but they antagonize each other [7].

As a member of the incretin family, GLP-1 is released from intestinal L-cells in response to dietary nutrient intake [14, 15]. Available data suggest that GLP-1 has many beneficial endocrine and metabolic effects including reduction of appetite and body weight, delay of gastric emptying, and decrease of blood sugar, mainly by promoting glucose-dependent insulin secretion [16, 17].
Impairment of taste is a complication of diabetes mellitus [18]. Chronic hyperglycemia can decrease an individual’s ability to detect and recognize sweet, salty, and bitter solutions [19]. Taste disturbances like ageusia (taste loss), hypogeusia (decrease in taste), and dysgeusia (abnormal taste) are important and easily neglected manifestations of diabetes [20].

Liraglutide has 97% sequence identity to native GLP-1 and contains an additional 16-carbon fatty acid that can serve as a long-acting GLP-1 receptor (GLP-1R) agonist. It is used for the treatment of type 2 diabetes mellitus (T2DM) and obesity [21], although the exact mechanisms by which liraglutide induces weight loss are not fully understood. Recently, we and other groups have separately found that GLP-1 and GLP-1R are expressed in the taste buds of both animals and humans, that GLP-1 signaling acts to enhance sweet taste sensitivity [10, 22], and that there are significant changes in these parameters in diabetic and/or obese individuals. This indicates that GLP-1 is an important peptide for the regulation of taste senses [23, 24]. Ramesh N et al. [25] recently reported that NUCB2/Nesfatin-1 was co-localized with incretins GLP-1 and glucose dependent insulino-tropic polypeptide (GIP) in mouse small intestinal cells and it stimulates both GLP-1 and GIP mRNA expression and secretion. However, there are few studies regarding the relationship between GLP-1 and NUCB2/nestatin-1 in taste buds or the hypothalamus. Therefore, the current study was designed to explore whether nestatin-1 is co-expressed with other appetites-regulating peptides in rat taste buds, and whether there are any changes in their relationship in diabetic and/or obese rats, especially after treatment with liraglutide.

Materials and Methods

Animals

Forty two male Wistar rats (purchased from Liaoning ChangSheng Biotechnology Co., Liaoning, China), weighing 180-200g, 8-10 weeks old, were individually housed under controlled room temperature (22±2ºC) and humidity (55±5%), with a 12:12 h light-dark cycle. Water and food were available ad libitum. All procedures adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. After a 1-week habituation, rats were randomly divided into high-fat (n= 30, diet contained 68% carbohydrate, 23% protein, 9% fat) diet groups. After 8 weeks, the rats fed a high-fat diet were treated by intraperitoneal injection of 30 mg/kg streptozotocin (Sigma-Aldrich, St. Louis, MO, USA), while NC rats received a comparable injection of saline. Seventy-two hours following the treatment, 24 rats with non-fasting blood glucose levels of ≥300 mg/dl (16.7mM) were considered T2DM rats [26] and continued on the high fat diet. Eight weeks later, 12 of these rats were treated daily with liraglutide (T2DM + LIR, 0.2 mg/kg, s.c.) for 4 weeks, the remaining 12 diabetic rats served as the diabetic control (T2DM-C) group. Both NC and T2DM-C rats were injected with saline once daily. Food intake was recorded twice a week and body weights (BWs) and non-fasting blood glucose (BG) levels were determined weekly.

Blood assays

After 4 weeks of treatment with liraglutide, fasted rats were injected intraperitoneally with 10% chloral hydrate (0.3ml/100g) after overnight food deprivation. BWs were measured and blood was drawn from the right ventricle. BG was assayed immediately by using the hexokinase method. Serum samples were stored at -80°C until assayed. Blood total triglyceride (TG) and cholesterol (TC) were measured by commercial assay kits (Huili Biotech, Changchun, China). Insulin (FINS) was quantified by an ELISA kit (EMD Millipore, Billerica, MA, USA).

Immunohistochemistry

Small blocks containing the circumvallate papillae (CV) of rats were quickly dissected immediately after euthanasia. The streptavidin–peroxidase (SP) method was used for immunohistochemical staining. Excised tissues were immersed in a solution of 4% paraformaldehyde for 24 h and processed for embedding in paraffin wax. The 7µm-thick sections were cut serially. Tissue sections were de-waxed and rehydrated, rinsed with distilled water and phosphate-buffered saline (PBS), quenched with 3% H2O2, and incubated with citrate buffer (pH 6.0) for 20 min at 100°C for antigen retrieval [27]. Then non-specific binding was reduced by pretreatment with 3% normal goat serum for 20 min and incubated with a rabbit polyclonal antibody against NUCB2/Nesfatin-1 (Phoenix Pharmaceuticals, Burlingame, CA, USA) at a dilution of 1:800 at 4°C overnight. In addition, in order to examine staining using adjacent slices, two adjacent slices were
Nesfatin-1 is expressed in taste buds.

USA) was used to perform statistical analyses. Results are expressed as means ± SEM. Data obtained from T2DM + LIR, T2DM-C and NC groups were examined by one-way ANOVA. Data handling and drawing were processed using GraphPad Prism (v6.0) software. A value of P < 0.05 was considered statistically significant.

Results

Body weight and food intake
T2DM-C and T2DM + LIR rats had similar BWs and food intake before liraglutide treatment. During the treatment period, T2DM + LIR rats showed gradually reduced BW gain (Fig. 1a) and then a significant mean BW loss (332 ± 7 to 309 ± 6 g) at the end of 4 weeks. In contrast, the T2DM-C group exhibited the highest mean levels of BW gain (Fig. 1b). Compared with the T2DM + LIR group, food intake was greater in the T2DM-C group, while the NC group showed the lowest food intake (Fig. 1c).

Blood assays
T2DM-C rats had the highest levels of BG, TG, TC, and FINS (Table 2). However, BG, TC, TG, and FINS were greater in the T2DM + LIR group than the NC group (Table 2).

Immunohistochemistry
Immunoreactivity for nesfatin-1 was observed in taste bud cells of rat CV. The nesfatin-1-immunoreactive cells were spindle-shaped, with large round nuclei. Immunoreactivity was confined to the cytosol (Fig. 2). We used α-gustducin antibody as a type 2 taste cells marker and further investigated that nesfatin-1 and α-gustducin were co-expressed in the type 2 taste cells by using adjacent slices (Fig. 3). The numbers of nesfatin-1 immunoreactive taste bud cells in each bud of the CV in T2DM-C rats were significantly less than those in the NC group (2.32±0.13 vs. 3.37±0.16, p<0.01). Interestingly, T2DM + LIR rats showed the most nesfatin-1 positive cells among three groups (T2DM + LIR vs. NC: 4.26±0.26 vs. 3.37±0.16, p<0.01) (Fig. 2).

Table 1 Sequences and efficiency of primers employed for RT-qPCR amplifications

<table>
<thead>
<tr>
<th>Gene</th>
<th>Genebank accession no.</th>
<th>Forward primer (5’-3’)</th>
<th>Reverse primer(5’-3’)</th>
<th>Product length(bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NUCB2</td>
<td>NM_021663.2</td>
<td>TTGAACACCTGAACACCCAG</td>
<td>AGTCCGGTCATACGTCCTCA</td>
<td>101 bp</td>
</tr>
<tr>
<td>Ghrelin</td>
<td>AB029433</td>
<td>TGGTGCTTCTACGGCATACATCT</td>
<td>CTGGCTTCTTTGCCTGCCCTCTCT</td>
<td>204 bp</td>
</tr>
<tr>
<td>β-Actin</td>
<td>NM_031144.3</td>
<td>GAGATTACTGCCCCGGCTGCTCTA</td>
<td>GACTCATCGTACCTCTGGCTGCTG</td>
<td>150 bp</td>
</tr>
</tbody>
</table>
RT-qPCR demonstrated that NUCB2 mRNA was highly expressed in the taste buds of rat CV. The relative expression of NUCB2 mRNA in taste buds in rat CV (11.32 ± 0.19) was at least 10-fold higher than in rat hypothalamus (Fig. 4) (P < 0.001).

In taste buds, the mean level of NUCB2 mRNA expression was significantly decreased in the T2DM-C group when compared with the NC group (Fig. 5) (P<0.001). T2DM + LIR rats showed the highest expression of NUCB2 mRNA (Fig. 5) (P<0.001). Compared with both the T2DM-C and T2DM + LIR groups, the mean level of ghrelin mRNA in the NC group was significantly reduced (Fig. 5) (P<0.001). However, there was no significant difference in ghrelin mRNA expression between the T2DM-C and T2DM + LIR groups (Fig. 5) (P>0.05).

In the hypothalamus, the mean expression of NUCB2 mRNA in the T2DM-C group was significantly increased compared to that in the NC or T2DM + LIR groups (Fig. 6) (P<0.001). The lowest level of NUCB2 expression was seen in the NC group (Fig. 6) (P<0.001). Compared with the NC group, the mean expression of ghrelin mRNA in the T2DM-C or T2DM + LIR groups was elevated Fig. 6) (p<0.001). It was unclear why the changes of mRNA expression of ghrelin in the hypothalamus became more obvious after liraglutide treatment compared to that in the T2DM-C group (Fig. 6) (p<0.001).

**Discussion**

There is a strong link between metabolic control and gustation. Taste perception plays a vital sensory role in determining what foodstuffs to ingest and in maintaining metabolic homeostasis. Nesfatin-1 is a gastrointestinal tract hormone classically considered to be associated with appetite control, glucose homeostasis, and slimness. Recent reports have indicated that many peptides in the gastrointestinal tract that regulate appe-
Nesfatin-1 is expressed in taste buds

Endocrine Journal  Advance Publication

Nesfatin-1 is co-expressed in taste bud cells [9-12], where they may play a modulatory role in fine tuning taste perception. Therefore, it is reasonable to speculate that nesfatin-1 is expressed in taste bud cells. In this study, we successfully verified the expression of nesfatin-1 in the type 2 taste buds of rat CV by immunohistochemical staining. It is reported that type 2 taste cells transduce sweet, bitter, or umami stimuli [29], and utilize a G protein-coupled transduction cascade for signaling [30, 31]. This result provides insights into the distinct functions of NUCB2/nesfatin-1 within the gustatory system, and suggests it has the potential to influence the amounts and types of food ingested.

Patients with T2DM often present with clinical symptoms of polyphagia, polydipsia, and polyuria. Chronic hyperglycemia in T2DM also can induce chronic complications that can affect almost every organ system of the body. Taste impairment is one such complication of T2DM [32]. However, the exact pathogenesis of taste impairment in diabetes is unclear.

Liraglutide, a classical GLP-1 analog, is used to treat T2DM. There is increasing evidence that liraglutide can reduce food intake, BW, and BG [21]. However, there is little known about the exact mechanism of GLP-1R agonists, especially in taste perception. In the current study, we successfully showed that:
1) NUCB2 mRNA is expressed in rat CV, 2) the expression level of NUCB2 mRNA is decreased in taste buds of T2DM-C rats, and 3) liraglutide treatment can significantly elevate the expression of NUCB2 mRNA in the CV of diabetic rats. These findings are beneficial to further understand the effects and interactions of nesfatin-1 and GLP-1 on the regulation of taste sensitivity, feeding, and energy balance, as well as the pathogenesis of obesity and/or diabetes.

The results of the current study showed that the expression of NUCB2 mRNA in the hypothalamus of T2DM-C rats was increased. This result is consistent with most previous studies [33] and suggested that NUCB2 secretion in the hypothalamus may be a compensatory mechanism in early stages of T2DM by suppressing food intake and reducing BW to improve insulin resistance and lipid metabolic disorders. However, in the hypothalamus, NUCB2 expression was decreased in T2DM + LIR compared to T2DM-C rats. These data suggest that in same situation, the expression of NUCB2 in taste buds and the hypothalamus may differ. However, the functional nature of these phenomena in terms of local or whole body biology remains to be explored.

In T2DM-C rats, the reduced expression of NUCB2 in CV taste buds may promote excess food intake and...
BW gain, while the elevation of NUCB2 expression in the hypothalamus may be an indirect compensation for decreased NUCB2 in the CV. We observed a decreased BW gain, food intake, and BG in T2DM + LIR rats. The increased NUCB2 in the CV induced by liraglutide might be involved in this effect. However, in the hypothalamus, the decreased expression of NUCB2 in T2DM + LIR rats should be a negative effect for weight loss. Nevertheless, the result was beneficial, although the mechanism remains unclear.

Interestingly, whether in taste buds or in hypothalamus, the expression of NUCB2 in T2DM + LIR group was actually higher than that of normal rats. A recent study by Katsurada et al. [34] indicated that endogenous GLP-1 targets the paraventricular nucleus to restrict feeding behavior. This implicates the projection from the nucleus tractus solitarius GLP-1 neurons, activation of corticotropin-releasing hormone, and NUCB2 neurons. Therefore, we think that liraglutide probably has a direct effect on the expression of nucleobindin-2 independent of the glycemic states.

Ghrelin opposes nesfatin-1 in the regulation of energy balance. In the current study, we found that, throughout the hypothalamus and CV, the mean level of ghrelin in either T2DM-C or T2DM + LIR rats was significantly higher than that in the NC group. Ghrelin levels were highest in T2DM + LIR rats, and never less than the T2DM-C group in the CV. The elevated expression of ghrelin in the hypothalamus of T2DM-C rats may be associated with increased caloric intake during the course of obesity-related T2DM. However, it is surprising that the mean expression level of ghrelin in T2DM + LIR rats was higher than that in the T2DM-C group. This finding indicates that, in the CV, ghrelin expression is independent of the GLP-1R pathway, while in the hypothalamus ghrelin secretion may be a compensatory response to liraglutide treatment.

The results of the current study firmly establish that nesfatin-1 and ghrelin are co-expressed in the taste buds of rat CV. Interestingly, the ghrelin level is elevated, while the NUCB2 level is decreased, in the CV of T2DM-C rats. This is consistent with the earlier finding that there is a reciprocal relationship between nesfatin-1 and ghrelin in gastrointestinal endocrine cells [7]. Our data further indicate that taste buds of rat CV, like gastric endocrine cells play an important role in regulating food intake. However, the situation appears to be different in the hypothalamus, which is a key integration area of the brain where numerous appetite-regulating peptides are released to participate in the control of energy homeostasis. In the arcuate nucleus of the hypothalamus, there are two distinct neuronal populations: one is a group of neurons co-expressing orexigenic neuropeptides, including neuropeptide Y and agouti-related protein; the other is a subset of neurons expressing anorexigenic neuropeptides, including proopiomelanocortin and cocaine- and amphetamine-regulated transcript. These are first-order neurons where peripheral metabolic signals, including peripheral adiposity signals (leptin, insulin, etc.), appetite regulating hormones (CCK, GLP-1, PYY, nesfatin-1, ghrelin, etc.), and nutrients are primarily transferred [35]. Therefore, the expression level of single or even double peptides such as nesfatin-1 or ghrelin in the hypothalamus may not fully reveal the complex network of hypothalamic appetite regulation.

In summary, nesfatin-1 is expressed in the type 2 taste bud cells of the CV. This indicates that nesfatin-1 may have some effects on the gustatory systems. The decreased expression of NUCB2 in the CV of T2DM-C rats is a possible cause of diabetic taste impairment. Moreover, liraglutide can regulate appetite and energy homeostasis through effects on the gustatory system. The increased expression of NUCB2 in the CV after liraglutide treatment might play a role in this effect. However, the results of the current study could not provide a definitive mechanism of liraglutide actions on the hypothalamus or the whole body. In T2DM rats, nesfatin-1 and ghrelin may be secreted simultaneously from the CV, but regulated individually to play opposite roles in appetite regulation. This suggests that the gustatory system is involved in the regulation of the body’s energy balance. The regulation of appetite involves complex mechanisms, many endocrine organs (hypothalamus, taste buds, gastrointestinal tract, etc.) and many hormone signals (nesfatin-1, ghrelin, GLP-1, etc.). Further studies designed to explore the interaction between NUCB2/nesfatin-1 and other appetite-regulatory peptides are needed.

Acknowledgments

The authors are grateful to all study participants.

Disclosure

The authors declare that there is no conflict of interest.
References


Nesfatin-1 is expressed in taste buds


